Please read full Prescribing Information for NUPLAZID, including Boxed WARNING.

Please read full Prescribing
Information for NUPLAZID, including Boxed WARNING.

 

HCP portal  /  Program Overview

 

support by your patient’s side.

 

Acadia Connect® is a support program connecting you, your staff, your patients, and their care partners with dedicated services throughout the treatment journey with NUPLAZID®.

 
Get Your Patient Started on NUPLAZID
 

Need assistance? Call us at 1-844-737-2223. Monday-Friday, 8:00 AM to 8:00 PM ET

 
A photo of a pair of hands holding someone else’s hand inside a heart shape
 

NUPLAZID® (pimavanserin) Free 30-Day Quick Start

Your patients may be eligible for the NUPLAZID Free 30-Day Quick Start. To select this option, complete the NUPLAZID Free 30-Day Quick Start section on the Prescription and Enrollment Form, or e-prescribe to RareMed Solutions.

Your patients may be eligible for a NUPLAZID Free 30-Day Quick Start.*

*Terms and conditions apply. Available for eligible patients starting therapy. This offer is limited to one per patient and is not transferable. The free trial is not health insurance.

Select RareMed Solutions in your Electronic Health Record (EHR) system when e‑prescribing NUPLAZID to submit an electronic prescription directly to Acadia Connect®.
OR

Submit the NUPLAZID Prescription and Enrollment form online

 
Complete and submit digital form
OR

Fax downloaded form to 1-844-737-2224 or email to [email protected]

 
Download Prescription
and Enrollment Form
 
Desktop calendar icon

Patients supported by Acadia Connect® receiving a free month trial are more likely to fill a NUPLAZID prescription.

76% of patients who received a free month trial of NUPLAZID with support from Acadia Connect® subsequently filled a prescription for NUPLAZID, whereas 59% of patients who were prescribed NUPLAZID but were not supported by Acadia Connect® and did not receive a free trial of NUPLAZID filled a prescription for NUPLAZID.

Picture of a woman wearing headphones with an Rx badge

Patients supported by Acadia Connect® receiving a free month trial fill NUPLAZID more times.

On average, patients who received a free month trial of NUPLAZID with support from Acadia Connect® subsequently filled NUPLAZID 12.1 times, whereas patients who were prescribed NUPLAZID but were not supported by Acadia Connect® and did not receive a free trial of NUPLAZID filled NUPLAZID an average of 8.6 times.

 

Free trial data reflect two consecutive free 14-day supplies provided through Acadia Connect®.

 
 

how does Acadia Connect® support your office?

 

Acadia Connect® helps ensure that it’s easy for your patients to start and continue NUPLAZID therapy. We’re here to support you, your staff, those prescribed NUPLAZID, and their care partners with access, insurance, affordability, and prescription assistance.

 

Acadia Connect®:

 
 
 

Acadia Connect®

 

more patients start. more patients stay.

 
Desktop calendar icon

More patients remain on NUPLAZID for one year when enrolled in Acadia Connect®.

At 12 months, 40% of patients referred through Acadia Connect® remained on NUPLAZID therapy, compared with 30% of patients whose prescriptions went directly to a specialty pharmacy without enrolling in Acadia Connect®.

Form with a white heart in top left corner

Patients enrolled in Acadia Connect® are more likely to remain on NUPLAZID therapy.

Patients supported by Acadia Connect® are more likely to remain on NUPLAZID therapy, averaging 30% more fills over the lifetime of the patient compared with patients whose prescriptions were sent directly to a specialty pharmacy without enrolling in Acadia Connect®.

 

Based on a retrospective analysis of Acadia HUB and specialty pharmacy data for referrals from January 1, 2021 through December 31, 2025 (data as of April 30, 2026); n=20,521 Acadia Connect®–supported referrals and n=17,887 direct-to-specialty-pharmacy referrals without a treatment form.

 
 

Your Acadia Connect® Team

 

who is the Acadia Connect® team?

Acadia Connect® consists of a dedicated, experienced support team:

 

Patient Access Manager (PAM)

The PAM offers education and support to assist you and your office with accessing NUPLAZID for your patients.

 
  • Provides information to minimize access barriers and coverage delays for NUPLAZID
  • Supports navigating prior authorizations, appeals, and reauthorizations by providing education on plan-specific coverage policies, requirements, and processes
  • Delivers updates on insurance status, potential financial assistance options, and any interruptions in a patient’s potential treatment

Long-Term Care (LTC) PAM

The LTC PAM offers education and support to help LTC healthcare providers (HCPs), their staff, and LTC facilities access NUPLAZID for residents.

 
  • Provides information to minimize access barriers and coverage delays for NUPLAZID
  • Supports navigating prior authorizations, appeals, and reauthorizations by providing education on plan-specific coverage policies, requirements, and processes
  • Delivers updates on insurance status, potential financial assistance options, and any interruptions in a patient’s potential treatment

Care Coordinator

When needed, the Care Coordinator provides your office staff with important information to help your patients start and continue potential treatment with NUPLAZID.

 
  • Provides benefits investigation and access support
  • Shares information on financial assistance options
  • Coordinates medication delivery
 
 

PAM locator tool

 

Connect with a PAM

 

The Patient Access Manager (PAM) offers education and support to assist you and your office with accessing NUPLAZID for your patients. Enter your ZIP code to locate your local PAM.

 
Ami, patient access manager
Ami, Patient Access Manager.
 
 

how does Acadia Connect® support your patients?

 

Once enrolled, each patient is paired with a dedicated Care Coordinator who handles the details – from insurance navigation to financial assistance to prescription delivery.

 
Shield featuring a white umbrella over a dark teal heart

Insurance Navigation

Prior authorization support, appeals assistance, and insurance approval guidance designed to simplify the access process for your patients.

White dollar sign inside teal circle with dark teal inner trim

Financial Support

Copay Program
Through the Acadia Connect® Commercial Copay Program, eligible commercially insured patients may pay as little as $0 per month.†

 

Patient Assistance Program
For patients who do not have insurance, or have situations in which NUPLAZID is not covered by their insurance plan, Acadia Connect® can provide financial assistance options such as the Acadia Connect® Patient Assistance Program.‡

Prescription pad with Rx in top left corner

Prescription and Delivery

Pharmacy coordination that helps ensure patients receive their medication on time and without interruption.

 

†For full program terms and conditions, please view here.

‡Terms and conditions apply. An application is required and is subject to review. Submission of an application does not guarantee approval for the program. While Acadia makes every effort to grant aid when needed and appropriate, the program is limited in available resources and may be modified or discontinued at any time without further notice.

 
 

get your patients started today.

 

Submit the NUPLAZID Prescription and Enrollment Form online

 
Prescribe & Enroll
 
Old-school phone receiver on a slant with a sound bubble coming from its middle

Call Acadia Connect®

1-844-737-2223

Monday-Friday, 8:00 AM to 8:00 PM ET

 
Important Safety Information and Indication for NUPLAZID® (pimavanserin)
 
 

Indication

 

NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

 
Important Safety Information
 
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
 
  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
  • NUPLAZID is not approved for the treatment of patients with dementia who experience psychosis unless their hallucinations and delusions are related to Parkinson’s disease.
 
  • Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.
  • Warnings and Precautions: QT Interval Prolongation
    • NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval (e.g., Class 1A antiarrhythmics, Class 3 antiarrhythmics, certain antipsychotics or antibiotics).
    • NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.
  • Adverse Reactions: The adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).
  • Drug Interactions:
    • Coadministration with strong CYP3A4 inhibitors increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.
    • Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.
 

Please read the full Prescribing Information, including Boxed WARNING, also available at NUPLAZIDhcp.com.

 
 
Dosage and Administration
 

Recommended dose: 34 mg capsule taken orally once daily, without titration, with or without food.

 

NUPLAZID is available as 34 mg capsules and 10 mg tablets.